Parkman Healthcare Partners LLC Makes New $6.47 Million Investment in Upstream Bio, Inc. $UPB

Parkman Healthcare Partners LLC acquired a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 935,247 shares of the company’s stock, valued at approximately $6,472,000.

Other hedge funds also recently modified their holdings of the company. Torren Management LLC bought a new stake in shares of Upstream Bio in the 4th quarter valued at $30,000. Persistent Asset Partners Ltd bought a new position in Upstream Bio during the second quarter worth $34,000. BNP Paribas Financial Markets boosted its stake in Upstream Bio by 229.8% during the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock worth $34,000 after acquiring an additional 2,158 shares in the last quarter. Legal & General Group Plc grew its holdings in Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after purchasing an additional 1,440 shares during the period. Finally, Empowered Funds LLC acquired a new stake in Upstream Bio in the fourth quarter worth $45,000.

Upstream Bio Price Performance

UPB opened at $6.61 on Tuesday. Upstream Bio, Inc. has a 1 year low of $5.85 and a 1 year high of $33.68. The firm’s fifty day moving average price is $6.88 and its two-hundred day moving average price is $8.74. The company has a market capitalization of $362.04 million, a price-to-earnings ratio of -2.28 and a beta of 1.26.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.01. The company had revenue of $0.77 million during the quarter, compared to analyst estimates of $0.56 million. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%. As a group, equities analysts anticipate that Upstream Bio, Inc. will post -2.86 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on UPB shares. Wall Street Zen downgraded shares of Upstream Bio from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Mizuho cut their price objective on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, May 14th. HC Wainwright started coverage on Upstream Bio in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 target price for the company. JPMorgan Chase & Co. boosted their target price on Upstream Bio from $8.00 to $9.00 and gave the company a “neutral” rating in a research report on Friday, August 14th. Finally, Weiss Ratings raised Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 17th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $29.67.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.